Skip to main content

Advertisement

Fig. 3 | Cancer Communications

Fig. 3

From: The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Fig. 3

Kaplan-Meier estimates of the survival of NPC patients with residual cervical lymphadenopathy. Of the 82 patients, 36 had detectable preoperative plasma EBV DNA, and 46 had undetectable preoperative plasma EBV DNA. a Progression-free survival; b overall survival; c distant metastasis-free survival; d locoregional relapse-free survival; e local relapse-free survival; and f regional relapse-free survival

Back to article page